Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: Results of the U.K. Dermatology Clinical Trials Network's PATCH II trial

British Journal of Dermatology

Volumn 166, Issue 1, 2012, Pages 169-178

  Thomas, Kim ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN V; PLACEBO;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CELLULITIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG WITHDRAWAL; ERYSIPELAS; FEMALE; HUMAN; LEG; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK REDUCTION; THRUSH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CELLULITIS; COSTS AND COST ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; LEG DERMATOSES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PENICILLIN V; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84555222395     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10586.x     Document Type: Article

References (30)

1. Cox NH, Colver GB, Paterson WD,. Management and morbidity of cellulitis of the leg. J R Soc Med 1998; 91: 634-7. (Pubitemid 29017595)
2. Carter K, Kilburn S, Featherstone P, et al. Cellulitis and treatment: a qualitative study of experiences. Br J Nurs 2007; 16: S22-4.
3. Levell N, Wingfield C, Garioch J,. Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary care. Br J Dermatol 2011; 164: 1326-8.
4. Haan MN, Selby JV, Quesenberry CP Jr, et al. The impact of aging and chronic disease on use of hospital and outpatient services in a large HMO: 1971-1991. J Am Geriatr Soc 1997; 45: 667-74. (Pubitemid 27248773)
5. Goettsch WG, Bouwes Bavinck JN, Herings RM,. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol 2006; 20: 834-9. (Pubitemid 44102917)
6. Cox NH,. Streptococcal cellulitis/erysipelas of the lower leg. In: Evidence-Based Dermatology (, Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B, eds), 2nd edn. Oxford: Blackwell Publishing, 2008; 413-14.
7. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318: 1591-4. (Pubitemid 29267772)
8. Roujeau JC, Sigurdsson AF, Korting HC, et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004; 209: 301-7.
9. Mokni M, Dupuy A, Denguezli M, et al. Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology 2006; 212: 108-12. (Pubitemid 43260724)
10. Cox NH,. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006; 155: 947-50. (Pubitemid 44564503)
11. Leclerc S, Teixeira A, Mahe E, et al. Recurrent erysipelas: 47 cases. Dermatology 2007; 214: 52-7. (Pubitemid 46033001)
12. Kremer M, Zuckerman R, Avraham Z, Raz R,. Long-term antimicrobial therapy in the prevention of recurrent sort-tissue infections. J Infect 1991; 22: 37-40.
13. Sjoblom AC, Eriksson B, Jorup-Ronstrom C, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993; 21: 390-3.
14. Chakroun M, Ben-Romdhane F, Battikh R, et al. Benzathine penicillin prophylaxis in recurrent erysipelas. Med Mal Infect 1994; 24: 894-7. (Pubitemid 24344274)
15. Clinical Resource Efficiency Support Team. Guidelines on the Management of Cellulitis in Adults. Belfast: CREST, 2005. Available at: (last accessed 20 September 2011).
16. Sanders CJ, Bruijnzeel-Koomen CA, Sanders CJG, Bruijnzeel-Koomen CAFM,. The practice guideline 'Bacterial skin infections' (first revision) from the Dutch College of General Practitioners; a response from the perspective of dermatology. Ned Tijdschr Geneeskd 2008; 152: 1604-5.
17. Dilemmas when managing cellulitis. Drug Ther Bull 2003; 41: 43-6.
18. U.K. Dermatology Clinical Trials Network's PATCH Study Group. Prophylactic antibiotics for the prevention of cellulitis. J Lymphoedema 2007; 2: 34-7.
19. Jorup-Ronstrom C, Britton S,. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection 1987; 15: 105-6. (Pubitemid 17051548)
20. The NHS Information Centre, Prescribing Support Unit. Prescription Cost Analysis, England 2009. NHS, Information Centre for Health and Social Care, 2010 (data by individual preparation). Available at: (last accessed 27 September 2011).
21. Curtis L,. Unit Costs of Health & Social Care 2009. Canterbury: Personal Social Services Research Unit, University of Kent, 2010. Available at: (last accessed 27 September 2011).
22. NHS. National Schedule of Reference Costs 2008-09 for NHS Trusts and PCTs. Department of Health, 2010. Available at: (last accessed 27 September 2011).
23. Barber JA, Thompson SG,. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000; 19: 3219-36.
24. Thomas KS, the U.K. Dermatology Clincial Trials Network's PATCH Study Group. Studying a disease with no home-lessons in trial recruitment from the PATCH II study. Trials 2010; 11: 22.
25. Hackshaw A, Kirkwood A,. Interpreting and reporting clinical trials with results of borderline significance. BMJ 2011; 343: d3340.
26. Kaplan EL, Johnson DR,. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicilllin V in eradication of group A streptococci from children with acute pharyngitis. Pediatrics 2001; 108: 1180-6. (Pubitemid 33021196)
27. Koster JB, Kullberg BJ, van der Meer JW, et al. Recurrent erysipelas despite antibiotic prophylaxis: an analysis from case studies. Neth J Med 2007; 65: 89-94. (Pubitemid 46487885)
28. de Godoy JMP, de Godoy MF, Valente A, et al. Lymphoscintigraphic evaluation in patients after erysipelas. Lymphology 2000; 33: 177-80. (Pubitemid 32063549)
29. Damstra RJ, van Steensel MAM, Boomsma JHB, et al. Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg. Br J Dermatol 2008; 158: 1210-15. (Pubitemid 351692855)
30. Horn DL, Zabriskie JB, Austrian R, et al. Why have group A streptococci remained susceptible to penicillin? Report on a symposium Clin Infect Dis 1998; 26: 1341-5. (Pubitemid 28270163)